An oral therapy with a unique targeted mechanism of action has been found effective for the control of ulcerative colitis in follow-up out to 52 weeks.
Ozanimod (Zeposia, Bristol Myers Squibb), a sphingosine-1-phosphate (SP1) receptor modulator, was effective regardless of whether patients had received prior therapy with a tumor necrosis factor inhibitor. The drug is FDA approved for the treatment of multiple sclerosis, but the new data support expanding its indications to include